4 unchanged sentences
3.3 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on March 28, 2014).
−Removed: 10.1*# Amendment #1 to the Supply Agreement, dated as of April 15, 2021, by and between Akebia Therapeutics, Inc, and STA Pharmaceutical Hong Kong Limited.
+Added: 10.1*† Form of Officer Performance-Based Stock Option Award, under the Company's 2014 Incentive Plan, as amended.
+Added: 10.2*† Form of Officer Performance-Based Restricted Stock Unit Award, under the Company's 2014 Incentive Plan, as amended.
+Added: 10.3*†# Form of Officer Cash Bonus Letter Agreement.
31.1* Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
10 unchanged sentences
# Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K
+Added: † Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AKEBIA THERAPEUTICS, INC.
−Removed: August 5, 2021
+Added: November 4, 2021
President and Chief Executive Officer (Principal Executive Officer)
−Removed: August 5, 2021
+Added: November 4, 2021
Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer)
−Removed: August 5, 2021
+Added: November 4, 2021
/s/ Violetta Cotreau
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.